Mebendazole 100 mg - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

endal worm treatment mebendazole 100 mg chewable tablet blister pack

sunmed pharma pty ltd - mebendazole, quantity: 100 mg - tablet, chewable - excipient ingredients: saccharin sodium; magnesium stearate; purified talc; maize starch; sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; purified water; polysorbate 80; sunset yellow fcf; flavour - treatment of enterobius vermicularis (threadworm or pinworm).,for the treatment of other worms such as ascaris lumbricoides (roundworm), trichuris trichura (whipworm) and ancylostoma duodenale and necator americanus (hookworm) only under medical supervision.

Australia - English - Department of Health (Therapeutic Goods Administration)

apohealth worm treatment mebendazole 100 mg chewable tablet blister pack (new formulation)

arrotex pharmaceuticals pty ltd - mebendazole, quantity: 100 mg - tablet, chewable - excipient ingredients: sodium starch glycollate type a; sunset yellow fcf; microcrystalline cellulose; polysorbate 80; maize starch; magnesium stearate; colloidal anhydrous silica; purified water; saccharin sodium; purified talc; flavour - treatment of enterobius vermicularis (threadworm or pinworm).,for the treatment of other worms such as ascaris lumbricoides (roundworm), trichuris trichura (whipworm) and ancylostoma duodenale and necator americanus (hookworm) only under medical supervision.

United States - English - NLM (National Library of Medicine)

vermox- mebendazole tablet, chewable

janssen pharmaceuticals, inc. - mebendazole (unii: 81g6i5v05i) (mebendazole - unii:81g6i5v05i) - mebendazole 500 mg - vermox™ chewable is indicated for the treatment of patients one year of age and older with gastrointestinal infections caused by ascaris lumbricoides (roundworm) and trichuris trichiura (whipworm). vermox™ chewable is contraindicated in persons with a known hypersensitivity to the drug or its excipients. risk summary the available published literature on mebendazole use in pregnant women has not reported a clear association between mebendazole and a potential risk of major birth defects or miscarriages [see data]. there are risks to the mother and fetus associated with untreated helminthic infection during pregnancy [see clinical considerations] . in animal reproduction studies, adverse developmental effects (i.e., skeletal malformations, soft tissue malformations, decreased pup weight, embryolethality) were observed when mebendazole was administered to pregnant rats during the period of organogenesis at single oral doses as low as 10 mg/kg (approximately 0.2-fold the maximum recommended human dose (mrhd))